Does the media prefer BMY or INDV?

In the previous week, Bloomsbury Publishing and Bloomsbury Publishing both had 1 articles in the media. Indivior's average media sentiment score of 0.67 beat Bloomsbury Publishing's score of 0.00 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bloomsbury Publishing 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BMY or HCM?

Bloomsbury Publishing presently has a consensus target price of GBX 792.50, suggesting a potential upside of 24.41%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts plainly believe Bloomsbury Publishing is more favorable than HUTCHMED. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bloomsbury Publishing 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to BMY or HCM?

In the previous week, Bloomsbury Publishing and Bloomsbury Publishing both had 1 articles in the media. HUTCHMED's average media sentiment score of 0.95 beat Bloomsbury Publishing's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bloomsbury Publishing 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VEC or BMY?

Bloomsbury Publishing has a consensus price target of GBX 792.50, suggesting a potential upside of 24.41%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts clearly believe Bloomsbury Publishing is more favorable than Vectura Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vectura Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bloomsbury Publishing 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate ERGO or BMY?

Bloomsbury Publishing has a consensus target price of GBX 792.50, suggesting a potential upside of 24.41%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, analysts plainly believe Bloomsbury Publishing is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bloomsbury Publishing 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend BMY or AMYT?

Bloomsbury Publishing presently has a consensus price target of GBX 792.50, suggesting a potential upside of 24.41%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, equities analysts plainly believe Bloomsbury Publishing is more favorable than Amryt Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bloomsbury Publishing 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Amryt Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Bloomsbury Publishing (BMY) Competitors

GBX 637 -2.00 (-0.31%)

As of 10/2/2026 12:00 PM Eastern

Compare

BMY vs. INDV, HCM, VEC, ERGO, and AMYT

Should you buy Bloomsbury Publishing stock or one of its competitors? Bloomsbury Publishing's main competitors and comparable companies include Indivior (INDV), HUTCHMED (HCM), Vectura Group (VEC), Ergomed (ERGO), and Amryt Pharma (AMYT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bloomsbury Publishing compare to Indivior?

Bloomsbury Publishing (LON:BMY) and Indivior (LON:INDV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, Bloomsbury Publishing and Bloomsbury Publishing both had 1 articles in the media. Indivior's average media sentiment score of 0.67 beat Bloomsbury Publishing's score of 0.00 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bloomsbury Publishing	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bloomsbury Publishing has higher earnings, but lower revenue than Indivior. Indivior is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bloomsbury Publishing	£325.90M	1.58	£37.37M	£32.80	19.42
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

Indivior has a net margin of 11.44% compared to Bloomsbury Publishing's net margin of 8.28%. Bloomsbury Publishing's return on equity of 12.74% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bloomsbury Publishing	8.28%	12.74%	7.82%
Indivior	11.44%	-23.90%	2.37%

Bloomsbury Publishing presently has a consensus price target of GBX 792.50, suggesting a potential upside of 24.41%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, equities analysts plainly believe Bloomsbury Publishing is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bloomsbury Publishing has a beta of 0.418, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

42.2% of Bloomsbury Publishing shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 3.6% of Bloomsbury Publishing shares are owned by insiders. Comparatively, 3.4% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bloomsbury Publishing pays an annual dividend of GBX 15.62 per share and has a dividend yield of 2.5%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. Bloomsbury Publishing pays out 47.6% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Bloomsbury Publishing beats Indivior on 12 of the 17 factors compared between the two stocks.

How does Bloomsbury Publishing compare to HUTCHMED?

Bloomsbury Publishing (LON:BMY) and HUTCHMED (LON:HCM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Bloomsbury Publishing presently has a consensus target price of GBX 792.50, suggesting a potential upside of 24.41%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts plainly believe Bloomsbury Publishing is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bloomsbury Publishing has a beta of 0.418, indicating that its stock price is 58% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, indicating that its stock price is 57% less volatile than the broader market.

HUTCHMED has a net margin of 163.84% compared to Bloomsbury Publishing's net margin of 8.28%. HUTCHMED's return on equity of 36.88% beat Bloomsbury Publishing's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bloomsbury Publishing	8.28%	12.74%	7.82%
HUTCHMED	163.84%	36.88%	-5.90%

42.2% of Bloomsbury Publishing shares are held by institutional investors. Comparatively, 20.7% of HUTCHMED shares are held by institutional investors. 3.6% of Bloomsbury Publishing shares are held by insiders. Comparatively, 2.8% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Bloomsbury Publishing and Bloomsbury Publishing both had 1 articles in the media. HUTCHMED's average media sentiment score of 0.95 beat Bloomsbury Publishing's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bloomsbury Publishing	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bloomsbury Publishing has higher earnings, but lower revenue than HUTCHMED. Bloomsbury Publishing is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bloomsbury Publishing	£325.90M	1.58	£37.37M	£32.80	19.42
HUTCHMED	£549.12M	3.40	-£52.98M	£2.00	107.50

Summary

Bloomsbury Publishing beats HUTCHMED on 8 of the 15 factors compared between the two stocks.

How does Bloomsbury Publishing compare to Vectura Group?

Vectura Group (LON:VEC) and Bloomsbury Publishing (LON:BMY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

In the previous week, Bloomsbury Publishing had 1 more articles in the media than Vectura Group. MarketBeat recorded 1 mentions for Bloomsbury Publishing and 0 mentions for Vectura Group. Vectura Group's average media sentiment score of 0.00 equaled Bloomsbury Publishing'saverage media sentiment score.

Company	Overall Sentiment
Vectura Group	Neutral
Bloomsbury Publishing	Neutral

Vectura Group pays an annual dividend of GBX 38 per share. Bloomsbury Publishing pays an annual dividend of GBX 15.62 per share and has a dividend yield of 2.5%. Vectura Group pays out 189.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bloomsbury Publishing pays out 47.6% of its earnings in the form of a dividend. Bloomsbury Publishing is clearly the better dividend stock, given its higher yield and lower payout ratio.

Bloomsbury Publishing has a consensus price target of GBX 792.50, suggesting a potential upside of 24.41%. Given Bloomsbury Publishing's stronger consensus rating and higher possible upside, analysts clearly believe Bloomsbury Publishing is more favorable than Vectura Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vectura Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

42.2% of Bloomsbury Publishing shares are held by institutional investors. 3.6% of Bloomsbury Publishing shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bloomsbury Publishing has a net margin of 8.28% compared to Vectura Group's net margin of 0.00%. Bloomsbury Publishing's return on equity of 12.74% beat Vectura Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vectura Group	N/A	N/A	N/A
Bloomsbury Publishing	8.28%	12.74%	7.82%

Bloomsbury Publishing has higher revenue and earnings than Vectura Group. Vectura Group is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vectura Group	£190.60M	0.00	N/A	£20.10	N/A
Bloomsbury Publishing	£325.90M	1.58	£37.37M	£32.80	19.42

Summary

Bloomsbury Publishing beats Vectura Group on 14 of the 14 factors compared between the two stocks.

How does Bloomsbury Publishing compare to Ergomed?

Ergomed (LON:ERGO) and Bloomsbury Publishing (LON:BMY) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Ergomed has a net margin of 9.87% compared to Bloomsbury Publishing's net margin of 8.28%. Ergomed's return on equity of 18.08% beat Bloomsbury Publishing's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ergomed	9.87%	18.08%	10.16%
Bloomsbury Publishing	8.28%	12.74%	7.82%

71.1% of Ergomed shares are owned by institutional investors. Comparatively, 42.2% of Bloomsbury Publishing shares are owned by institutional investors. 18.2% of Ergomed shares are owned by company insiders. Comparatively, 3.6% of Bloomsbury Publishing shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ergomed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Bloomsbury Publishing has a beta of 0.418, meaning that its stock price is 58% less volatile than the broader market.

In the previous week, Bloomsbury Publishing had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Bloomsbury Publishing and 0 mentions for Ergomed. Ergomed's average media sentiment score of 0.00 equaled Bloomsbury Publishing'saverage media sentiment score.

Company	Overall Sentiment
Ergomed	Neutral
Bloomsbury Publishing	Neutral

Bloomsbury Publishing has higher revenue and earnings than Ergomed. Ergomed is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ergomed	£152.09M	0.00	£15M	£0.29	N/A
Bloomsbury Publishing	£325.90M	1.58	£37.37M	£32.80	19.42

Bloomsbury Publishing has a consensus target price of GBX 792.50, suggesting a potential upside of 24.41%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, analysts plainly believe Bloomsbury Publishing is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Ergomed and Bloomsbury Publishing tied by winning 7 of the 14 factors compared between the two stocks.

How does Bloomsbury Publishing compare to Amryt Pharma?

Bloomsbury Publishing (LON:BMY) and Amryt Pharma (LON:AMYT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bloomsbury Publishing	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amryt Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bloomsbury Publishing has higher revenue and earnings than Amryt Pharma. Amryt Pharma is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bloomsbury Publishing	£325.90M	1.58	£37.37M	£32.80	19.42
Amryt Pharma	£210.24M	0.00	N/A	-£33.00	N/A

42.2% of Bloomsbury Publishing shares are owned by institutional investors. 3.6% of Bloomsbury Publishing shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bloomsbury Publishing has a net margin of 8.28% compared to Amryt Pharma's net margin of 0.00%. Bloomsbury Publishing's return on equity of 12.74% beat Amryt Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bloomsbury Publishing	8.28%	12.74%	7.82%
Amryt Pharma	N/A	N/A	N/A

In the previous week, Bloomsbury Publishing had 1 more articles in the media than Amryt Pharma. MarketBeat recorded 1 mentions for Bloomsbury Publishing and 0 mentions for Amryt Pharma. Bloomsbury Publishing's average media sentiment score of 0.00 equaled Amryt Pharma'saverage media sentiment score.

Company	Overall Sentiment
Bloomsbury Publishing	Neutral
Amryt Pharma	Neutral

Summary

Bloomsbury Publishing beats Amryt Pharma on 12 of the 12 factors compared between the two stocks.

Get Bloomsbury Publishing News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMY vs. The Competition

Export

Metric	Bloomsbury Publishing	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£514.97M	£12.24B	£7.16B	£2.46B
Dividend Yield	2.54%	2.64%	2.54%	6.18%
P/E Ratio	19.42	799.70	275.67	366.16
Price / Sales	1.58	938.84	656.66	89,492.78
Price / Cash	8.91	86.66	78.87	27.89
Price / Book	2.56	10.46	10.93	6.83
Net Income	£37.37M	£2.84B	£3.51B	£5.89B
7 Day Performance	2.74%	-1.56%	-2.00%	-0.72%
1 Month Performance	1.93%	-5.58%	-6.19%	-1.01%
1 Year Performance	26.89%	-2.40%	8.03%	22.82%

Bloomsbury Publishing Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMY Bloomsbury Publishing	2.4122 of 5 stars	GBX 637 -0.3%	GBX 792.50 +24.4%	+26.9%	£514.97M	£325.90M	19.42	34,300	News Coverage
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+0.0%	£1.93B	£1.40B	N/A	1,000	News Coverage Gap Up High Trading Volume
HCM HUTCHMED	N/A	GBX 210 -3.2%	N/A	-11.2%	£1.83B	£549.12M	105.00	1,760	Gap Down
VEC Vectura Group	N/A	N/A	N/A	N/A	£1.01B	£190.60M	8.20	9,200
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BMY) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bloomsbury Publishing (BMY) Competitors

BMY vs. INDV, HCM, VEC, ERGO, and AMYT

How does Bloomsbury Publishing compare to Indivior?

Summary

How does Bloomsbury Publishing compare to HUTCHMED?

Summary

How does Bloomsbury Publishing compare to Vectura Group?

Summary

How does Bloomsbury Publishing compare to Ergomed?

Summary

How does Bloomsbury Publishing compare to Amryt Pharma?

Summary

Media Sentiment Over Time

BMY vs. The Competition

Bloomsbury Publishing Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bloomsbury Publishing (BMY) Competitors

BMY vs. INDV, HCM, VEC, ERGO, and AMYT

How does Bloomsbury Publishing compare to Indivior?

Does the media prefer BMY or INDV?

Which has better earnings and valuation, BMY or INDV?

Is BMY or INDV more profitable?

Do analysts rate BMY or INDV?

Which has more volatility & risk, BMY or INDV?

Do institutionals & insiders have more ownership in BMY or INDV?

Is BMY or INDV a better dividend stock?

Summary

How does Bloomsbury Publishing compare to HUTCHMED?

Do analysts prefer BMY or HCM?

Which has more risk and volatility, BMY or HCM?

Is BMY or HCM more profitable?

Do insiders & institutionals hold more shares of BMY or HCM?

Does the media refer more to BMY or HCM?

Which has higher earnings and valuation, BMY or HCM?

Summary

How does Bloomsbury Publishing compare to Vectura Group?

Does the media refer more to VEC or BMY?

Is VEC or BMY a better dividend stock?

Do analysts prefer VEC or BMY?

Do insiders & institutionals hold more shares of VEC or BMY?

Is VEC or BMY more profitable?

Which has better valuation and earnings, VEC or BMY?

Summary

How does Bloomsbury Publishing compare to Ergomed?

Is ERGO or BMY more profitable?

Do insiders & institutionals hold more shares of ERGO or BMY?

Which has more volatility & risk, ERGO or BMY?

Does the media favor ERGO or BMY?

Which has preferable valuation and earnings, ERGO or BMY?

Do analysts rate ERGO or BMY?

Summary

How does Bloomsbury Publishing compare to Amryt Pharma?

Do analysts recommend BMY or AMYT?

Which has better valuation and earnings, BMY or AMYT?

Do institutionals and insiders hold more shares of BMY or AMYT?

Is BMY or AMYT more profitable?

Does the media refer more to BMY or AMYT?

Summary

Media Sentiment Over Time

BMY vs. The Competition

Bloomsbury Publishing Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools